Human Aging and in Vivo Noradrenergic System (NA_PET_MRI)

Civil Hospices of Lyon

Status

Unknown

Conditions

Parkinson Disease

Treatments

Other: The role of the noradrenergic system across the life span (Parkinson's Disease Subjects)

Other: The role of the noradrenergic system across the life span (Healthy Subjects)

Study type

Interventional

Funder types

Other

Identifiers

NCT03942289

69HCL18_0409

2018-003999-13 (EudraCT Number)

Details and patient eligibility

About

The main goal of this research proposal is to provide, for the first time in humans, a wider understanding of the role of the noradrenergic system both in health and illness (Parkinson's disease) through the use of a newly developed radiotracer (11Carbon [11C]Yohimbine) visualizing alpha-2 (α2) adrenergic receptors (AR) combined with cutting-edge technology, the hybrid positron emission tomography (PET)/magnetic resonance imaging (MRI) scanner. The secondary aim of this study will be to determine whether the expected age- and Parkinson's disease (PD)-related changes in the noradrenergic system are paralleled by changes in neuropsychological performances (such as cognitive, motor and/or olfactory abilities).

Enrollment

135 estimated patients

Sex

All

Ages

20 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for the healthy controls:

Age between 20 years and 80 years
Weight between 40 kilograms (kg) and 95kg
Without neurologic or psychiatric history
Without head trauma history including loss of consciousness superior to 30 minutes.
Affiliated to a social security or similar scheme
Not subject to any legal protection measures
Participant must have signed an informed consent document indicating that they understand the purpose of, and procedures required for, the study and are willing to participate in the study and comply with the study procedures and restrictions

Inclusion Criteria for the patients with Parkinson's disease:

Age between 40 and 80 years old
Weight between 40 kilograms (kg) and 95kg
With an idiopathic Parkinson's disease (Dopa-sensitive)
Without head trauma history including loss of consciousness superior to 30 minutes.
Affiliated to a social security or similar scheme
Not subject to any legal protection measures
Participant must have signed an informed consent document indicating that they understand the purpose of, and procedures required for, the study and are willing to participate in the study and comply with the study procedures and restrictions

Exclusion Criteria:

Subject with alcohol or substance abuse history
Subject with somatic drug therapies
Magnetic Resonance Imaging (MRI) contraindications (implanted or embedded metal objects in the head or body)
Positron Emission Tomography (PET) contraindications
Exposed to 1 millisievert or more of ionizing radiation in the year before the start of this study
Subject unable to sign written consent for participation in the study